每周特立帕肽给药在骨质疏松相关腰椎退行性疾病后路或经椎间孔腰椎椎间融合术后六个月内促进骨性融合的作用:多中心前瞻性随机研究
多中心前瞻性随机研究纳入75例≥50岁女性骨质疏松相关腰椎退行性疾病患者,随机接受术后每周特立帕肽皮下注射6个月或不使用特立帕肽。改良意向治疗分析显示术后4个月特立帕肽组2个中心CT层面骨融合显著高于对照组,符合方案分析显示6个月时显著更高;两组的JOA-BPEQ和ODI术后均改善。
要点
- 术后4个月2个中心CT层面骨融合在年龄调整改良意向治疗分析中特立帕肽组显著高于对照组。
- 符合方案分析中术后6个月骨融合特立帕肽组显著高于对照组。
- JOA-BPEQ和ODI结果在两组术后均改善。
核心结论
- 每周给予特立帕肽促进手术融合部位的骨形成并减少骨吸收,骨代谢标志物结果提示这一作用出现在术后早期。
- 作者认为,腰椎椎间融合联合特立帕肽治疗可能是管理老年腰椎退行性疾病的有效选择。
研究设计与样本
- 多中心前瞻性随机研究,纳入≥50岁女性,骨密度低于性别匹配年轻成人均值80%和/或既往脊柱压缩性骨折或股骨骨折,且患有腰椎退行性疾病。
- 患者随机分配至特立帕肽组(术后第1周开始每周皮下注射特立帕肽,持续6个月)或对照组(不使用特立帕肽)。
- 采用动态X线摄影和计算机断层扫描(CT)进行盲法放射学评估,并进行改良意向治疗分析和符合方案分析。
- 采用日本骨科协会背痛评估问卷(JOA-BPEQ)和Oswestry功能障碍指数(ODI)评估临床和神经症状。
- 75例患者被随机分配接受治疗,66例完成治疗。
主要发现
- 术后4个月,年龄调整改良意向治疗分析显示,2个中心CT层面骨融合特立帕肽组显著高于对照组。
- 符合方案分析显示,术后6个月骨融合特立帕肽组显著高于对照组。
- 放射学检查显示无椎间盘间隙狭窄和椎间盘不稳。
- JOA-BPEQ和ODI结果在两组术后均改善。
关键数值与推荐
- 术后4个月2个中心CT层面骨融合在年龄调整改良意向治疗分析中特立帕肽组显著高于对照组。
- 符合方案分析中术后6个月骨融合特立帕肽组显著高于对照组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For elderly patients, posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) is usually performed to treat lumbar degenerative diseases. However, some patients exhibit pseudarthrosis following such procedures. The anabolic agent teriparatide is an approved treatment for promoting bone formation in osteoporotic patients. Our multicenter, prospective randomized study assessed the role of once-weekly teriparatide administration on patient outcomes following interbody fusion. METHODS: Patients were females who were ≥50 years of age, had a bone mineral density (BMD) of <80% of the sex-matched young adult mean and/or previous spinal compression or femoral fractures, and had lumbar degenerative disease. Patients were randomly allocated to receive either weekly teriparatide, administered subcutaneously starting at week 1, for 6 months postoperatively (the teriparatide arm), or no teriparatide (the control arm). Blinded radiographic evaluations were performed using dynamic radiography and computed tomography (CT) and assessed by modified intention-to-treat analysis and per-protocol analysis. Clinical and neurological symptoms were evaluated using the Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOA-BPEQ) and the Oswestry Disability Index (ODI). RESULTS: Seventy-five patients were randomized to treatment, and 66 patients completed treatment. At 4 months postoperatively, bone fusion in the 2 center CT slices was significantly higher in the teriparatide arm compared with the control arm in the age-adjusted modified intention-to-treat analysis and was significantly higher at 6 months in the per-protocol analysis. Radiographic examinations showed no disc-space narrowing and no intervertebral disc instability. JOA-BPEQ and ODI results were improved postoperatively in both treatment arms. CONCLUSIONS: Weekly administration of teriparatide promoted bone formation at the surgical fusion site and decreased bone resorption, as indicated by bone metabolic marker results, within the early postoperative period. Our findings suggest that combining lumbar interbody fusion and teriparatide treatment may be an effective option for managing lumbar degenerative disease in elderly patients. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
引用
- Ebata S, Takahashi J, Hasegawa T, et al. Role of Weekly Teriparatide Administration in Osseous Union Enhancement within Six Months After Posterior or Transforaminal Lumbar Interbody Fusion for Osteoporosis-Associated Lumbar Degenerative Disorders: A Multicenter, Prospective Randomized Study. J Bone Joint Surg Am. 2017. PMID: 28244906. doi:10.2106/JBJS.16.00230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。